Drugs / Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00993447 Comparator | Oct 2009 → Sep 2011 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00993447 ↗ |
| Modality | Vaccine | “tetanus/diphtheria/acellular pertussis vaccine as third injection” PMID 24067553 ↗ Oct 2013 |